

# Montserrat Alegret

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6302697/publications.pdf>

Version: 2024-02-01

64  
papers

2,993  
citations

185998

28  
h-index

182168

51  
g-index

66  
all docs

66  
docs citations

66  
times ranked

7117  
citing authors

#	ARTICLE	IF	CITATIONS
1	Analysis of shared heritability in common disorders of the brain. <i>Science</i> , 2018, 360, .	6.0	1,085
2	A Longitudinal Follow-Up of 550 Mild Cognitive Impairment Patients: Evidence for Large Conversion to Dementia Rates and Detection of Major Risk Factors Involved. <i>Journal of Alzheimer's Disease</i> , 2013, 34, 769-780.	1.2	164
3	Genome-wide association analysis of dementia and its clinical endophenotypes reveal novel loci associated with Alzheimer's disease and three causality networks: The GR@ACE project. <i>Alzheimer's and Dementia</i> , 2019, 15, 1333-1347.	0.4	111
4	The membrane-spanning 4-domains, subfamily A (MS4A) gene cluster contains a common variant associated with Alzheimer's disease. <i>Genome Medicine</i> , 2011, 3, 33.	3.6	81
5	Cut-off Scores of a Brief Neuropsychological Battery (NBACE) for Spanish Individual Adults Older than 44 Years Old. <i>PLoS ONE</i> , 2013, 8, e76436.	1.1	69
6	Design of a comprehensive Alzheimer's disease clinic and research center in Spain to meet critical patient and family needs. <i>Alzheimer's and Dementia</i> , 2014, 10, 409-415.	0.4	69
7	Efficacy and Safety of Plasma Exchange with 5% Albumin to Modify Cerebrospinal Fluid and Plasma Amyloid- $\beta^2$ Concentrations and Cognition Outcomes in Alzheimer's Disease Patients: A Multicenter, Randomized, Controlled Clinical Trial. <i>Journal of Alzheimer's Disease</i> , 2017, 56, 129-143.	1.2	67
8	Normative data of a brief neuropsychological battery for Spanish individuals older than 49. <i>Journal of Clinical and Experimental Neuropsychology</i> , 2012, 34, 209-219.	0.8	63
9	Ecological assessment of executive functions in mild cognitive impairment and mild Alzheimer's disease. <i>Journal of the International Neuropsychological Society</i> , 2009, 15, 751-757.	1.2	59
10	A Two-Year Follow-Up of Cognitive Deficits and Brain Perfusion in Mild Cognitive Impairment and Mild Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2012, 30, 109-120.	1.2	59
11	PLD3 in non-familial Alzheimer's disease. <i>Nature</i> , 2015, 520, E3-E5.	13.7	58
12	Type 2 diabetes is an independent risk factor for dementia conversion in patients with mild cognitive impairment. <i>Journal of Diabetes and Its Complications</i> , 2017, 31, 1272-1274.	1.2	54
13	Usefulness of peripapillary nerve fiber layer thickness assessed by optical coherence tomography as a biomarker for Alzheimer's disease. <i>Scientific Reports</i> , 2018, 8, 16345.	1.6	52
14	Alzheimer's disease risk variants modulate endophenotypes in mild cognitive impairment. <i>Alzheimer's and Dementia</i> , 2016, 12, 872-881.	0.4	50
15	Risk of progression to Alzheimer's disease for different neuropsychological Mild Cognitive Impairment subtypes: A hierarchical meta-analysis of longitudinal studies. <i>Psychology and Aging</i> , 2018, 33, 1007-1021.	1.4	46
16	The Role of Verb Fluency in the Detection of Early Cognitive Impairment in Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2018, 62, 611-619.	1.2	39
17	CALHM1 P86L Polymorphism is Associated with Late-Onset Alzheimer's Disease in a Recessive Model. <i>Journal of Alzheimer's Disease</i> , 2010, 20, 247-251.	1.2	38
18	Plasma A $\beta$ 42/40 ratio alone or combined with FDG-PET can accurately predict amyloid-PET positivity: a cross-sectional analysis from the AB255 Study. <i>Alzheimer's Research and Therapy</i> , 2019, 11, 96.	3.0	38

#	ARTICLE	IF	CITATIONS
19	Dementia Care in Times of COVID-19: Experience at Fundació ACE in Barcelona, Spain. <i>Journal of Alzheimer's Disease</i> , 2020, 76, 33-40.	1.2	38
20	Estrogen receptor alpha gene variants are associated with Alzheimer's disease. <i>Neurobiology of Aging</i> , 2012, 33, 198.e15-198.e24.	1.5	36
21	Blood Amyloid Beta Levels in Healthy, Mild Cognitive Impairment and Alzheimer's Disease Individuals: Replication of Diastolic Blood Pressure Correlations and Analysis of Critical Covariates. <i>PLoS ONE</i> , 2013, 8, e81334.	1.1	36
22	Comparative Cognitive Effects of Choreographed Exercise and Multimodal Physical Therapy in Older Adults with Amnesic Mild Cognitive Impairment: Randomized Clinical Trial. <i>Journal of Alzheimer's Disease</i> , 2020, 73, 769-783.	1.2	36
23	Neuropsychiatric profiles and conversion to dementia in mild cognitive impairment, a latent class analysis. <i>Scientific Reports</i> , 2021, 11, 6448.	1.6	36
24	Exploring APOE genotype effects on Alzheimer's disease risk and amyloid $\beta$ burden in individuals with subjective cognitive decline: The Fundació ACE Healthy Brain Initiative (FACEHBI) study baseline results. <i>Alzheimer's and Dementia</i> , 2018, 14, 634-643.	0.4	33
25	Visual impairment in aging and cognitive decline: experience in a Memory Clinic. <i>Scientific Reports</i> , 2019, 9, 8698.	1.6	32
26	Brain Perfusion Correlates of Visuo-perceptual Deficits in Mild Cognitive Impairment and Mild Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2010, 21, 557-567.	1.2	30
27	Cognitive, Genetic, and Brain Perfusion Factors Associated with Four Year Incidence of Alzheimer's Disease from Mild Cognitive Impairment. <i>Journal of Alzheimer's Disease</i> , 2014, 41, 739-748.	1.2	30
28	Concordance between Subjective and Objective Memory Impairment in Volunteer Subjects. <i>Journal of Alzheimer's Disease</i> , 2015, 48, 1109-1117.	1.2	30
29	The Spanish version of Face-Name Associative Memory Exam (S-FNAME) performance is related to amyloid burden in Subjective Cognitive Decline. <i>Scientific Reports</i> , 2018, 8, 3828.	1.6	28
30	Impact of Recruitment Methods in Subjective Cognitive Decline. <i>Journal of Alzheimer's Disease</i> , 2017, 57, 625-632.	1.2	26
31	Cognitive Composites Domain Scores Related to Neuroimaging Biomarkers within Probable-Amnesic Mild Cognitive Impairment-Storage Subtype. <i>Journal of Alzheimer's Disease</i> , 2017, 57, 447-459.	1.2	26
32	A computerized version of the Short Form of the Face-Name Associative Memory Exam (FACEmemory®) for the early detection of Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2020, 12, 25.	3.0	24
33	Association between retinal thickness and $\beta$ -amyloid brain accumulation in individuals with subjective cognitive decline: Fundació ACE Healthy Brain Initiative. <i>Alzheimer's Research and Therapy</i> , 2020, 12, 37.	3.0	24
34	Validation of the Spanish Version of the Face Name Associative Memory Exam (S-FNAME) in Cognitively Normal Older Individuals. <i>Archives of Clinical Neuropsychology</i> , 2015, 30, 712-720.	0.3	22
35	Genome-wide significant risk factors on chromosome 19 and the APOE locus. <i>Oncotarget</i> , 2018, 9, 24590-24600.	0.8	22
36	Evaluation of macular thickness and volume tested by optical coherence tomography as biomarkers for Alzheimer's disease in a memory clinic. <i>Scientific Reports</i> , 2020, 10, 1580.	1.6	22

#	ARTICLE	IF	CITATIONS
37	Identification of Misdiagnosed Fronto-Temporal Dementia using APOE Genotype and Phenotype-Genotype Correlation Analyses. <i>Current Alzheimer Research</i> , 2014, 11, 182-191.	0.7	22
38	Patient Engagement: The Fundació ACE Framework for Improving Recruitment and Retention in Alzheimer's Disease Research. <i>Journal of Alzheimer's Disease</i> , 2018, 62, 1079-1090.	1.2	20
39	Four year follow-up study after unilateral pallidotomy in advanced Parkinson's disease. <i>Journal of Neurology</i> , 2002, 249, 1671-1677.	1.8	17
40	Neuropsychological, neuropsychiatric, and quality of life assessments in Alzheimer's disease patients treated with plasma exchange with albumin replacement from the randomized AMBAR study. <i>Alzheimer's and Dementia</i> , 2022, 18, 1314-1324.	0.4	17
41	Genetic association of complement receptor 1 polymorphism rs3818361 in Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2011, 7, e124-9.	0.4	16
42	Matrix metalloproteinase 10 is linked to the risk of progression to dementia of the Alzheimer's type. <i>Brain</i> , 2022, 145, 2507-2517.	3.7	16
43	Exploratory analysis of seven Alzheimer's disease genes: disease progression. <i>Neurobiology of Aging</i> , 2013, 34, 1310.e1-1310.e7.	1.5	15
44	Establishing In-House Cutoffs of CSF Alzheimer's Disease Biomarkers for the AT(N) Stratification of the Alzheimer Center Barcelona Cohort. <i>International Journal of Molecular Sciences</i> , 2022, 23, 6891.	1.8	13
45	Exploring Genetic Associations of Alzheimer's Disease Loci With Mild Cognitive Impairment Neurocognitive Endophenotypes. <i>Frontiers in Aging Neuroscience</i> , 2018, 10, 340.	1.7	12
46	From Face-to-Face to Home-to-Home: Validity of a Teleneuropsychological Battery. <i>Journal of Alzheimer's Disease</i> , 2021, 81, 1541-1553.	1.2	11
47	Association of TMEM106B rs1990622 Marker and Frontotemporal Dementia: Evidence for a Recessive Effect and Meta-Analysis. <i>Journal of Alzheimer's Disease</i> , 2014, 43, 325-334.	1.2	9
48	Beneficial Effects of an Integrated Psychostimulation Program in Patients with Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2016, 50, 559-566.	1.2	9
49	Social Representation of Dementia: An Analysis of 5,792 Consecutive Cases Evaluated in a Memory Clinic. <i>Journal of Alzheimer's Disease</i> , 2017, 58, 1099-1108.	1.2	9
50	Neuropsychiatric Profile as a Predictor of Cognitive Decline in Mild Cognitive Impairment. <i>Frontiers in Aging Neuroscience</i> , 2021, 13, 718949.	1.7	9
51	Identification of undiagnosed dementia cases using a web-based pre-screening tool: The MOPEAD project. <i>Alzheimer's and Dementia</i> , 2021, 17, 1307-1316.	0.4	8
52	Automatized FACEmemory® scoring is related to Alzheimer's disease phenotype and biomarkers in early-onset mild cognitive impairment: the BIOFACE cohort. <i>Alzheimer's Research and Therapy</i> , 2022, 14, 43.	3.0	8
53	Personality Factors and Subjective Cognitive Decline: The FACEHBI Cohort. <i>Behavioural Neurology</i> , 2020, 2020, 1-6.	1.1	7
54	BIOFACE: A Prospective Study of Risk Factors, Cognition, and Biomarkers in a Cohort of Individuals with Early-Onset Mild Cognitive Impairment. Study Rationale and Research Protocols. <i>Journal of Alzheimer's Disease</i> , 2021, 83, 1233-1249.	1.2	7

#	ARTICLE	IF	CITATIONS
55	The MTHFD1L Gene rs11754661 Marker is Not Associated with Alzheimer's Disease in a Sample of the Spanish Population. <i>Journal of Alzheimer's Disease</i> , 2011, 25, 47-50.	1.2	5
56	Subtle executive deficits are associated with higher brain amyloid burden and lower cortical volume in subjective cognitive decline: the FACEHBI cohort. <i>Scientific Reports</i> , 2020, 10, 17721.	1.6	5
57	Validation and Normative Data of the Spanish Version of the Face Name Associative Memory Exam (S-FNAME). <i>Journal of the International Neuropsychological Society</i> , 2022, 28, 74-84.	1.2	5
58	Letter Verbal Fluency in Spanish-, Basque-, and Catalan-Speaking Individuals: Does the Selection of the Letters Influence the Outcome?. <i>Journal of Speech, Language, and Hearing Research</i> , 2019, 62, 2400-2410.	0.7	5
59	Evaluation of Candidate Genes Related to Neuronal Apoptosis in Late-Onset Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2015, 45, 621-629.	1.2	4
60	Clinical Applicability of the Specific Risk Score of Dementia in Type 2 Diabetes in the Identification of Patients with Early Cognitive Impairment: Results of the MOPEAD Study in Spain. <i>Journal of Clinical Medicine</i> , 2020, 9, 2726.	1.0	4
61	Complementary pre-screening strategies to uncover hidden prodromal and mild Alzheimer's disease: Results from the MOPEAD project. <i>Alzheimer's and Dementia</i> , 2021, , .	0.4	3
62	Utilidad de la Lista de Palabras de la Wechsler Memory Scale-III para valorar la memoria episódica verbal en la evaluación forense. <i>Revista Espanola De Medicina Legal</i> , 2013, 39, 78-81.	0.3	1
63	Utilidad del subtest Semejanzas de la Escala de Inteligencia de Wechsler para Adultos-III y su relación con la conciencia de déficit en la evaluación forense del deterioro cognitivo. <i>Revista Espanola De Medicina Legal</i> , 2014, 40, 170-174.	0.3	0
64	Valoración de las funciones viso-perceptivas y viso-espaciales en la práctica forense. <i>Revista Espanola De Medicina Legal</i> , 2014, 40, 83-85.	0.3	0